While the results from a completed phase 1 study with IPI-926 in combination with FOLFIRINOX in PDA have suggested potential clinical activity [32], the cumulative results observed with this group of agents suggest that the continued investigation of SHh inhibitors in pancreas cancer is unlikely to be yielding any meaningful efficacy. The gene discussed is SHH; the disease is Patent ductus arteriosus.